{"id":386,"date":"2024-08-20T09:19:50","date_gmt":"2024-08-20T01:19:50","guid":{"rendered":"https:\/\/flcube.com\/?p=386"},"modified":"2024-10-13T18:44:33","modified_gmt":"2024-10-13T10:44:33","slug":"genmabs-tepkinly-epkinly-receives-ec-nod-for-relapsed-lymphoma-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=386","title":{"rendered":"Genmab’s Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments"},"content":{"rendered":"\n

COPENHAGEN\u2014Genmab A\/S (NASDAQ: GMAB<\/a>), a leading biotech company, has announced that the European Commission (EC) has granted market approval for its Tepkinly\/Epkinly (epcoritamab), a CD3\/CD20 bispecific T cell engager. The drug is indicated for third-line or later treatment of relapsed or refractory (R\/R) follicular lymphoma (FL) and R\/R diffuse large B-cell lymphoma (DLBCL), marking it as the first subcutaneous bispecific T-cell engager approved for this patient population in Europe.<\/p>\n\n\n\n

The approval follows a 2020 deal between Genmab and US pharmaceutical giant AbbVie (NYSE: ABBV<\/a>), which saw the two companies co-developing up to three bispecific T-cell engager candidates globally. The agreement included a substantial upfront payment of USD 750 million and potential milestone payments of up to USD 3.15 billion to Genmab. The drug has already received two approvals from the US FDA, first for R\/R DLBCL in May 2023 and later for third-line treatment of R\/R FL in February this year.<\/p>\n\n\n\n

The EC’s conditional approval was supported by data from the Phase I\/II EPCORE NHL-1 clinical trial, which demonstrated an overall response rate (ORR) of 83% and a complete response (CR) rate of 63% in patients treated with Tepkinly. The median duration of response was 21.4 months, indicating a promising therapeutic effect. The drug’s administration mechanism, designed to mitigate cytokine release syndrome (CRS), resulted in no Grade 3 or higher CRS cases.<\/p>\n\n\n\n

This regulatory milestone underscores Genmab’s commitment to expanding access to innovative therapies for patients with difficult-to-treat lymphomas and strengthens its position in the global oncology market.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

COPENHAGEN\u2014Genmab A\/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,368,28,851,853,15],"class_list":["post-386","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-genmab","tag-multi-specific-antibodies","tag-nasdaq-gmab","tag-nyse-abbv","tag-product-approvals"],"yoast_head":"\nGenmab's Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genmab A\/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC) has granted market approval for its Tepkinly\/Epkinly (epcoritamab), a CD3\/CD20 bispecific T cell engager. The drug is indicated for third-line or later treatment of relapsed or refractory (R\/R) follicular lymphoma (FL) and R\/R diffuse large B-cell lymphoma (DLBCL), marking it as the first subcutaneous bispecific T-cell engager approved for this patient population in Europe.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab's Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-20T01:19:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:44:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genmab’s Tepkinly\\\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments\",\"datePublished\":\"2024-08-20T01:19:50+00:00\",\"dateModified\":\"2024-10-13T10:44:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386\"},\"wordCount\":266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Genmab\",\"Multi-specific antibodies\",\"NASDAQ: GMAB\",\"NYSE: ABBV\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=386#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=386\",\"name\":\"Genmab's Tepkinly\\\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-20T01:19:50+00:00\",\"dateModified\":\"2024-10-13T10:44:33+00:00\",\"description\":\"Genmab A\\\/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC) has granted market approval for its Tepkinly\\\/Epkinly (epcoritamab), a CD3\\\/CD20 bispecific T cell engager. The drug is indicated for third-line or later treatment of relapsed or refractory (R\\\/R) follicular lymphoma (FL) and R\\\/R diffuse large B-cell lymphoma (DLBCL), marking it as the first subcutaneous bispecific T-cell engager approved for this patient population in Europe.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=386\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genmab’s Tepkinly\\\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genmab's Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments - Insight, China's Pharmaceutical Industry","description":"Genmab A\/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC) has granted market approval for its Tepkinly\/Epkinly (epcoritamab), a CD3\/CD20 bispecific T cell engager. The drug is indicated for third-line or later treatment of relapsed or refractory (R\/R) follicular lymphoma (FL) and R\/R diffuse large B-cell lymphoma (DLBCL), marking it as the first subcutaneous bispecific T-cell engager approved for this patient population in Europe.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=386","og_locale":"en_US","og_type":"article","og_title":"Genmab's Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=386","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-20T01:19:50+00:00","article_modified_time":"2024-10-13T10:44:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genmab’s Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments","datePublished":"2024-08-20T01:19:50+00:00","dateModified":"2024-10-13T10:44:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=386"},"wordCount":266,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Genmab","Multi-specific antibodies","NASDAQ: GMAB","NYSE: ABBV","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=386#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=386","url":"https:\/\/flcube.com\/?p=386","name":"Genmab's Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-20T01:19:50+00:00","dateModified":"2024-10-13T10:44:33+00:00","description":"Genmab A\/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC) has granted market approval for its Tepkinly\/Epkinly (epcoritamab), a CD3\/CD20 bispecific T cell engager. The drug is indicated for third-line or later treatment of relapsed or refractory (R\/R) follicular lymphoma (FL) and R\/R diffuse large B-cell lymphoma (DLBCL), marking it as the first subcutaneous bispecific T-cell engager approved for this patient population in Europe.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=386"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genmab’s Tepkinly\/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=386"}],"version-history":[{"count":4,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/386\/revisions"}],"predecessor-version":[{"id":5979,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/386\/revisions\/5979"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}